Medindia

X

Scale Venture Partners Had 6 Exits and Invested Over $100M in 29 Companies in 2007

Tuesday, January 22, 2008 General News J E 4
Advertisement
FOSTER CITY, Calif., Jan. 22 Scale Venture Partners todayannounced significant progress in 2007 with six liquidity events, includingfour acquisitions, two initial public offerings and an additional IPO filing.ScaleVP invested $107 million in 29 companies, five of which were new ScaleVPinvestments. Also in 2007, the firm re-launched as Scale Venture Partners,following the completion of its first institutional fundraising.

"Our first full year as Scale Venture Partners exceeded our expectations,"said Kate Mitchell, Managing Director, ScaleVP. "We used our expertise, trackrecord and networks to source new deals in a number of our focus areas,including consumer electronics, Internet marketing, mobile entertainment andopen source software. Each of these new portfolio companies -- Discera,Vantage Media, Waterfront Media, PlayPhone and Jaspersoft -- has built market-disrupting technologies and business models that intersect significant markettrends."

"In addition to the acquisitions of Good Technology, Esurg Holdings,Picolight and Pavilion Technologies, two of our portfolio companies alsocompleted IPOs. Orexigen, a 2005 investment which went public in April 2007,has seen strong mid-stage trial results for its pharmaceutical treatments forobesity, a continuing global health concern and a major focus of ours," saidLou Bock, Managing Director, ScaleVP. "Glu Mobile, a 2004 investment, wentpublic in March 2007 and continues to take advantage of a growing globalinterest in mobile entertainment. IPC, which filed an S-1 in September,announced this month that it has set its IPO terms."

"Looking forward, our insight-driven investment strategy will continue in2008 as we track technology and healthcare trends that are driving significantgrowth and large-market opportunities," said Rory O'Driscoll, ManagingDirector, ScaleVP. "For example, we are looking closely at the expansion ofopen source software (OSS) in the enterprise market, low-cost computingsolutions and regenerative medical technologies as potential additions to ourportfolio this coming year."

New Fund, New People and Promotions

In 2007, ScaleVP announced that it had completed its first institutionalfinancing: Scale Venture Partners Fund II, a $400 million fund with thebacking of 12 long-term Limited Partners. In personnel news, ScaleVP waspleased to announce the appointment of Mary Denten as CFO and Dana Maness asController. ScaleVP also promoted healthcare team member Nancy Lynch, M.D., toPrincipal. Nancy's prior experience as a practicing physician has helpedScaleVP source and build its healthcare portfolio. In the fourth quarter,Karan Mehandru joined as an Associate on the technology team. Karan bringssignificant work experience at Synopsys and PMC Sierra.

About Scale Venture Partners

Based in Foster City, California, the ScaleVP team is a long-standingpartnership with a consistent, top quartile track record of returns. ScaleVenture Partners' insight-driven investment strategy, extensive operatingnetworks and go-to-market expertise help identify and build winning portfoliocompanies in technology and healthcare markets. The ScaleVP team's provenskill-set and active approach provides entrepreneurs a competitive advantagefor growth and category leadership. Representative portfolio companies includeAlimera Sciences, Discera, Frontbridge, Glu Mobile, mBlox, Monolithic PowerSystems, National Healing, NComputing, Omniture, Orexigen, ScanSafe, Somaxon,Vantage Media, Waterfront Media, Xceive and Zogenix. For more information,visit www.scalevp.com.New Investments During 2007 Discera - MEMS-based frequency and timing controls JasperSoft - open source business intelligence PlayPhone - mobile entertainment site; powers subscription-based portals, too Vantage Media - search marketing for the education sector Waterfront Media - network of health, diet and fitne
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
DuPont Delivers Strong Fourth Quarter, Full-Year S...
S
Exelixis and Bristol-Myers Squibb to Co-Develop XL...